Overview

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2025-10-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.

Phase:

Phase 1

Details

Lead Sponsor:

Allogene Therapeutics

Treatments:

Cyclophosphamide
Fludarabine